Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England

被引：36

作者：

Wells, Philippa M. ^{[1
]}

Doores, Katie J. ^{[2
]}

Couvreur, Simon ^{[1
]}

Nunez, Rocio Martinez ^{[2
]}

Seow, Jeffrey ^{[2
]}

Graham, Carl ^{[2
]}

Acors, Sam ^{[2
]}

Kouphou, Neophytos ^{[2
]}

Neil, Stuart J. D. ^{[2
]}

Tedder, Richard S. ^{[3
]}

Matos, Pedro M. ^{[2
]}

Poulton, Kate ^{[2
]}

Lista, Maria Jose ^{[2
]}

Dickenson, Ruth E. ^{[2
]}

Sertkaya, Helin ^{[2
]}

Maguire, Thomas J. A. ^{[4
]}

Scourfield, Edward J. ^{[2
]}

Bowyer, Ruth C. E. ^{[1
]}

Hart, Deborah ^{[1
]}

O'Byrne, Aoife ^{[4
]}

Steel, Kathryn J. A. ^{[4
]}

Hemmings, Oliver ^{[5
]}

Rosadas, Carolina ^{[3
]}

McClure, Myra O. ^{[3
]}

Capedevilla-pujol, Joan ^{[6
]}

Wolf, Jonathan ^{[6
]}

Ourselin, Sebastien ^{[7
]}

Brown, Matthew A. ^{[8
,9
]}

Malim, Michael H. ^{[2
]}

Spector, Tim ^{[1
]}

Steves, Claire J. ^{[1
]}

机构：

[1] Kings Coll London, Dept Twin Res, St Thomas Hosp, London SE1 7EH, England

[2] Kings Coll London, Sch Immunol & Microbial Sci, Dept Infect Dis, London, England

[3] Imperial Coll London, cDept Infect Dis, London, England

[4] Kings Coll London, Sch Immunol & Microbial Sci, Dept Inflammat Biol, Ctr Inflammat Biol & Canc Immunol, London, England

[5] Kings Coll London, Sch Immunol & Microbial Sci, Dept Immunobiol, London, England

[6] Zoe Global Ltd, Westminster Bridge Rd, London, England

[7] Kings Coll London, Sch Biomed Engn & Imaging Sci, London, England

[8] Guys & St ThomasHosp NHS Trust, Dept Med & Mol Genet, London, England

[9] Kings Coll London NIHR Biomed Res Ctr, London, England

来源：

JOURNAL OF INFECTION | 2020年 / 81卷 / 06期

基金：

英国惠康基金; 英国医学研究理事会;

关键词：

COVID-19; SARS-CoV-2; Population; Asymptomatic; Antibody; Immunity; Seropoprevalence; Anosmia; UK;

D O I：

10.1016/j.jinf.2020.10.011

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background: Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. Methods: We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million. Findings: We demonstrated a seroprevalence of 12% (51 participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive. Interpretation: Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response. (C) 2020 Published by Elsevier Ltd on behalf of The British Infection Association.

引用

页码：931 / 936

页数：6

共 19 条

[1]

[Anonymous], 2020, REGIONAL ETHNIC DIVE

[2]

[Anonymous], PLoS Pathog, DOI DOI 10.1371/JOURNAL.PPAT.1009035

[3]

[Anonymous], 2020, COR COVID 19 INF COM

[4]

[Anonymous], 2020, Covid Symptom Study

[5]

Bataille V., 2020, 2020071020150656 MED

[6]

Department for Communities and Local Government, 2019, English indices of deprivation 2019

[7] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial [J].

Folegatti, Pedro M. ;

Ewer, Katie J. ;

Aley, Parvinder K. ;

Angus, Brian ;

Becker, Stephan ;

Belij-Rammerstorfer, Sandra ;

Bellamy, Duncan ;

Bibi, Sagida ;

Bittaye, Mustapha ;

Clutterbuck, Elizabeth A. ;

Dold, Christina ;

Faust, Saul N. ;

Finn, Adam ;

Flaxman, Amy L. ;

Hallis, Bassam ;

Heath, Paul ;

Jenkin, Daniel ;

Lazarus, Rajeka ;

Makinson, Rebecca ;

Minassian, Angela M. ;

Pollock, Katrina M. ;

Ramasamy, Maheshi ;

Robinson, Hannah ;

Snape, Matthew ;

Tarrant, Richard ;

Voysey, Merryn ;

Green, Catherine ;

Douglas, Alexander D. ;

Hill, Adrian V. S. ;

Lambe, Teresa ;

Gilbert, Sarah C. ;

Pollard, Andrew J. .

LANCET, 2020, 396 (10249) :467-478

[8]

Gallais F., 2020, Methodes qualitatives, quantitatives et mixtes: dans la recherche en sciences humaines, sociales et de la Sante

[9] SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls [J].

Le Bert, Nina ;

Tan, Anthony T. ;

Kunasegaran, Kamini ;

Tham, Christine Y. L. ;

Hafezi, Morteza ;

Chia, Adeline ;

Chng, Melissa Hui Yen ;

Lin, Meiyin ;

Tan, Nicole ;

Linster, Martin ;

Chia, Wan Ni ;

Chen, Mark I-Cheng ;

Wang, Lin-Fa ;

Ooi, Eng Eong ;

Kalimuddin, Shirin ;

Tambyah, Paul Anantharajah ;

Low, Jenny Guek-Hong ;

Tan, Yee-Joo ;

Bertoletti, Antonio .

NATURE, 2020, 584 (7821) :457-+

[10]

Lista M.J., 2020, RESILIENT SARS COV 2

← 1 2 →